Navigation Links
New Data Demonstrated Efficacy and Safety of Initial Combination Therapy with Welchol(R) (colesevelam HCl) and Metformin in Drug-Naive Adult Type 2 Diabetes Patients
Date:6/26/2010

cebo (n=141) along with open-label metformin (initiated at 850 mg/d; uptitrated to 1700 mg/d thereafter).  Mean baseline A1C levels were 7.8 percent in the Welchol plus metformin group and 7.5 percent in the metformin plus placebo group.

The study found that initial combination therapy with Welchol and metformin reduced mean A1C levels by 1.1 percent compared with patients receiving metformin plus placebo (-0.8 percent), resulting in a mean treatment difference of -0.3 percent (p<0.01). The study also showed that 67 percent of patients (n=66) achieved the A1C target of less than 7 percent with Welchol plus metformin, compared with 56 percent of patients (n=53) receiving metformin plus placebo, a statistically significant difference (p<0.01).  Additionally, 48 percent of patients (n=61) in the Welchol group attained LDL cholesterol less than 100 mg/dL compared with 18 percent of patients (n=24) in the metformin plus placebo group (p<0.0001).

Welchol in combination with metformin also resulted in significantly greater mean reductions in LDL cholesterol levels (16 percent), mean total cholesterol levels (6 percent), mean non-HDL cholesterol (8 percent), mean apolipoprotein B (8 percent), and median high sensitivity C-reactive protein (hs-CRP) (17 percent) compared with patients treated with metformin plus placebo, (p<0.01 for all). In the study, Welchol plus metformin increased triglycerides by 19 percent (p<0.001) compared with metformin plus placebo.  

Results from a safety analysis of this study showed that initial combination therapy with Welchol and metformin was well-tolerated and had a safety profile similar to that of metformin monotherapy. Compliance with the individual treatment components was greater than 90 percent for both groups.  In patients receiving Welchol plus metformin, the most common gastrointestinal adverse events wer
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Data Show Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Demonstrated Significant ADHD Symptom Reduction when Assessed Using the Oppositional Subscale of the Conners ADHD Rating Scale
2. ULORIC(R) (febuxostat) Demonstrated Efficacy for Management of Hyperuricemia in Patients with Gout
3. Solos Endoscopy, Inc.s MammoView(TM) Product Line to be Demonstrated at the 95th Annual American College of Surgeons Clinical Congress
4. Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study
5. 5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH
6. Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients
7. IMPACT Study Showed Longer Valcyte(R) (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protection Against Cytomegalovirus (CMV) Disease One Year Post-Transplant
8. New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
9. Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
10. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
11. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015 Research and Markets ( ... "The Corporate Reputation of Pharma - The ... report to their offering. The ... now in its fourth edition. This report contains ... For each annual Corporate Reputation report, the author ...
(Date:4/17/2015)... April 17, 2015 Sigma-Aldrich Corporation ... Science and High Technology company, today announced the ... headquarters and state-of-the-art Cell Culture Technical Center ... facility will provide customized support to meet customer ... "Our new Technical Center will significantly ...
(Date:4/17/2015)... TWi Pharmaceuticals, Inc. ("TWi", Stock Ticker:4180.TT) today ... USA , has obtained state sales licenses from ... been in close contact with the major nationwide retail ... own label specialty generic products sold through these nationwide ... According to IMS Health, the U.S. pharma ...
Breaking Medicine Technology:The Corporate Reputation of Pharma - The Global Patient Perspective in 2014 2Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 2Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 3Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 4Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 5
... HealthCare Inc. (OTC Pink: MHCC) announced the appointment of ... Millennium President Chris Amandola commented, "Ed brings deep experience ... have him join our advisory board.  Our Company,s advantage ... and resourceful individuals and he will be a tremendous ...
... ABT ) today announced that the U.S. Food ... Self-Expanding Stent System for the treatment of iliac artery ... affects the lower extremities. Over time, iliac artery disease ... experience chronic pain and suffer permanent disability. This approval ...
Cached Medicine Technology:Millennium HealthCare Appoints Ed Joyce to Company Advisory Board 2Abbott's Absolute Pro® Vascular Self-Expanding Stent System Receives FDA Approval for Treatment of Iliac Artery Disease 2Abbott's Absolute Pro® Vascular Self-Expanding Stent System Receives FDA Approval for Treatment of Iliac Artery Disease 3Abbott's Absolute Pro® Vascular Self-Expanding Stent System Receives FDA Approval for Treatment of Iliac Artery Disease 4
(Date:4/18/2015)... (PRWEB) April 18, 2015 Review of ... hosting a ‘Strategies for Success’ program for cataract surgeons ... meeting in San Diego, where eye surgeon Jeffrey L. ... this invitation-only event. Dr. Martin is the Managing Partner ... of Ophthalmology chose Dr. Martin to lead this year’s ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 Thousand of ... on behalf of individuals who were allegedly harmed by ... to move forward in the U.S. District Court, Northern ... 10th, the Court has amended an earlier Case Management ... Among other things, the new amendment permits the claims ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 “ ArcAngel ” ... which takes a look at the latest and coolest ... Joe Troohey, the host of AppWatch and technology expert, conducted ... a personal safety app. , In a turbulent world, ... help. Calling 911 should always be their first move, but ...
(Date:4/17/2015)... 2015 Rosetta Radiology is proud to ... their list of diagnostic imaging services. This solidifies them ... the Upper East Side of Manhattan. , The new ... The addition of PET-CT, combined with Rosetta’s state of ... to work with patients through several stages of the ...
(Date:4/17/2015)... “We have seen healing, a lot of healing, and ... Chaplain Shawn Kafader of Friendship Village. “People have found ... to contribute have created beautiful pieces of art.” For the ... program that was launched to benefit residents of the retirement ... the Art Institute in Chicago, worked as an intern at ...
Breaking Medicine News(10 mins):Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:Healing At Friendship Village Due To Art Therapy 2
... impairment appears to be more common in people with ... a report in the October issue of Archives ... journals. , Approximately 14.6 million Americans had diagnosed ... undiagnosed diabetes, according to background information in the article. ...
... deprived of body,s sleep-wake system ,can,t remember anything, study ... body clock may do more than help guide your ... vital role in learning and memory, say Stanford University ... a functioning circadian system is critical to the rodents, ...
... Earnings Conference Call on October 30 - - Presentation at Oppenheimer,s 19th Annual Healthcare ... ... ... 7 -, SAN DIEGO, Oct. 13 Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today ...
... Oshkosh is one of six sites included in national ... because of low cardiac arrest survival rates, OSHKOSH, ... ) announced today that it has,received an additional $1.5 ... to continue a study testing two devices used in ...
... Content Rights Management System, Supports Global Pharma ... Spend, WEST CHESTER, Pa., Oct. 13 ... manufacturer has integrated,Modevity,s Imperium technology to become the ... tracking and reporting,analytics for their new product video ...
... Away, FORT WORTH, Texas, Oct. 13 The ... at the Will Rogers Memorial,Center. The company, which has ... bottles of free Dannon smoothies and demonstrated support,for a ... FitFuture KIDS Fest is to help educate families about ...
Cached Medicine News:Health News:Vision loss more common in people with diabetes 2Health News:Circadian Rhythm Plays Role in Memory 2Health News:Gen-Probe Announces Webcasts of Three Upcoming Investor Events 2Health News:Gen-Probe Announces Webcasts of Three Upcoming Investor Events 3Health News:Advanced Circulatory Systems Receives $1.5 Million From NIH for Study of Cardiac Arrest Resuscitation Techniques 2Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:The Dannon Company Sponsors FitFuture KIDS Fest 2Health News:The Dannon Company Sponsors FitFuture KIDS Fest 3
... The new Eyewear ... lifestyle proposition, encompassing elegance, ... well as a dedication ... Mirroring key attributes of ...
The license agreement for the manufacturing and distribution of Bulgari eyewear was signed by Luxottica Group in 1997.,Bulgari eyewear is designed for sleek, select people who want to distinguish the...
The Aristar collection offers high quality, fashionable eyewear at exceptional pricing. Classic shapes updated with contemporary designs allow both men and women alike to enjoy superior craftsmanship...
... Glamour and style. Creativity and cutting-edge design. ... companies, signed a new licensing agreement in ... formed in 1985 by the famous designer ... blended sensuality with their Mediterranean roots to ...
Medicine Products: